News & Updates

Show Multimedia Only

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

10 Sep 2025 by

A 45-year-old female with a sedentary lifestyle presented with lower extremity oedema in 2023. She was slightly overweight (26 kg/m²) and had no prior history of cardiac disease. Her busy lifestyle precluded regular health check-ups.

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

10 Sep 2025

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

09 Sep 2025 by

In patients with established coronary artery disease (CAD), clopidogrel appears to provide superior protection against major adverse cardiovascular or cerebrovascular events (MACCE) without increasing the risk of bleeding when compared with aspirin, according to a meta-analysis.

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

09 Sep 2025

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

09 Sep 2025 by

Data presented at ESMO Gyn 2025 support apixaban as a prophylactic agent for venous thromboembolism (VTE) in women with epithelial ovarian cancer who are undergoing neoadjuvant chemotherapy consisting of carboplatin and paclitaxel.

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

09 Sep 2025

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

08 Sep 2025

The use of propafenone shows no significant relationship with an elevated risk of proarrhythmia and mortality compared with amiodarone in atrial fibrillation (AF) patients with heart failure (HF), suggests a recent study.

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

08 Sep 2025

Alirocumab lowers LDL-C levels in patients with ACS

08 Sep 2025

Long-term treatment with alirocumab with or without lipid-lowering therapy treatment significantly reduced the levels of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS), as shown by the results of a real-world evidence study.

Alirocumab lowers LDL-C levels in patients with ACS

08 Sep 2025

Short-term exposure to ozone air pollution ups risks of hospital admissions for MI, stroke

07 Sep 2025

Individuals with short-term exposure to ozone (O3) air pollution are at risk of myocardial infarction (MI) and stroke requiring hospitalization, according to a systematic review and meta-analysis.

Short-term exposure to ozone air pollution ups risks of hospital admissions for MI, stroke

07 Sep 2025

One surgery saved three lives: Bentall procedure in a woman with aortic dissection and preterm twin pregnancy

02 Sep 2025 by

A multidisciplinary team (MDT) at Prince Wales Hospital (PWH) and the Chinese University of Hong Kong (CUHK) successfully performed an emergency Bentall procedure in a pregnant woman with acute type A aortic dissection and preterm twins. The patient survived and her healthy twins were delivered 6 weeks later.

One surgery saved three lives: Bentall procedure in a woman with aortic dissection and preterm twin pregnancy

02 Sep 2025

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025 by

The primary results of the phase III SELECT-GCA trial underpin the potential of upadacitinib plus a glucocorticoid taper (GC-T) for the treatment of giant-cell arteritis (GCA).

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025

SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome

31 Aug 2025 by

In the treatment of patients with stage 4 cardiovascular–kidney–metabolic (CKM) syndrome, sodium–glucose cotransporter 2 (SGLT2) inhibitors appear to exert cardio- and renoprotective effects, as shown in a retrospective study.

SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome

31 Aug 2025

SGLT2 inhibitors lower stroke, mortality risks in AF patients with T2DM

29 Aug 2025

Treatment with SGLT2 inhibitors appears to reduce the risks of stroke, dementia, long-standing persistent atrial fibrillation (AF), heart failure, and mortality in patients with both AF and type 2 diabetes mellitus (T2DM), suggests a recent study.

SGLT2 inhibitors lower stroke, mortality risks in AF patients with T2DM

29 Aug 2025

News & Updates

Showing Cardiology articles

Showing

Specialty:

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

Marked improvement of LVEF with an SGLT2i in a patient with nonischaemic HFrEF

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

Alirocumab lowers LDL-C levels in patients with ACS

Alirocumab lowers LDL-C levels in patients with ACS

Short-term exposure to ozone air pollution ups risks of hospital admissions for MI, stroke

Short-term exposure to ozone air pollution ups risks of hospital admissions for MI, stroke

One surgery saved three lives: Bentall procedure in a woman with aortic dissection and preterm twin pregnancy

One surgery saved three lives: Bentall procedure in a woman with aortic dissection and preterm twin pregnancy

Upadacitinib bumps up GCA treatment armamentarium

Upadacitinib bumps up GCA treatment armamentarium

SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome

SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome

SGLT2 inhibitors lower stroke, mortality risks in AF patients with T2DM

SGLT2 inhibitors lower stroke, mortality risks in AF patients with T2DM